(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

VARIANTES DE G-CSF PORCINO, COMPOSIÇÃO FARMACÊUTICA QUE COMPREENDE AS MESMAS E USOS TERAPÊUTICOS DAS DITAS VARIANTES

Em ExigênciaInvention PatentPCT · US2018055203 Official document available

Application data

Number

112020007037

Type

Invention Patent

Filing

10/10/2018

Publication

11/17/2020

PCT

US2018055203

Patent grant document available

We have the complete official document for this filing, as published by INPI.

Access the document

Progress at the INPI

Technical opinion to answer
  1. Filing10/10/18
  2. Publication11/17/20
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 08/12/2025. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

AMBRX, INC.

US

ELANCO US INC.

US

See this company's full portfolio

Inventors

M. R. (pessoa física)

US

N. K. (pessoa física)

US

P. C. (pessoa física)

US

Technical data

Priority claims

US

62/570,877 · 10/11/2017

Abstract

A presente invenção refere-se a variantes de fator estimulante de colônia de granulócitos porcinos (pG-CSF). As variantes de pG-CSF são úteis no tratamento, prevenção ou redução da incidência de infecções bacterianas em suínos. Métodos de tratamento de suínos são revelados.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Parecer de pré-exame

#6.23

08/12/2025

RPI 2849

Adição na publicação

#15.35

12/07/2021

RPI 2657

Notificação de entrada na fase nacional - PCT

#1.3

11/17/2020

RPI 2602

Alteração de dados cadastrais

#1.1

09/15/2020

RPI 2593

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.